

Resource Summary Report

Generated by [RRID](#) on Aug 19, 2026

[pBABEpuro-ERBB2](#)

RRID:Addgene_40978

Type: Plasmid

Proper Citation

RRID:Addgene_40978

Plasmid Information

URL: <http://www.addgene.org/40978>

Proper Citation: RRID:Addgene_40978

Insert Name: ERBB2

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:22908275](#)

Vector Backbone Description: Backbone Size:5200; Vector Backbone:pBABE-puro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: pBABEpuro-ERBB2

Record Creation Time: 20220422T222212+0000

Record Last Update: 20260815T081440+0000

Ratings and Alerts

No rating or validation information has been found for pBABEpuro-ERBB2.

No alerts have been found for pBABEpuro-ERBB2.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gagnon KA, et al. (2026) Oncogenic Alterations in PI3K Signaling Emulated Optogenetically Recapitulate Some Phenotypic Changes in Mammary Epithelia. *ACS synthetic biology*, 15(2), 561.

Dacheux MA, et al. (2025) BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling. *bioRxiv : the preprint server for biology*.

Montero-Vergara J, et al. (2024) GRB2 is a BECN1 interacting protein that regulates autophagy. *Cell death & disease*, 15(1), 14.

Momeny M, et al. (2024) DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. *EMBO molecular medicine*, 16(7), 1603.

Dennis M, et al. (2024) Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells. *PLoS genetics*, 20(5), e1011293.

McKernan CM, et al. (2022) ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. *Cell reports*, 40(9), 111268.

Song X, et al. (2021) FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. *Investigational new drugs*, 39(5), 1201.

Reche-Perez FJ, et al. (2021) Single chain variable fragment fused to maltose binding protein: a modular nanocarrier platform for the targeted delivery of antitumorals. *Biomaterials science*, 9(5), 1728.

Akhand SS, et al. (2021) Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. *NPJ breast cancer*, 7(1), 5.

Koivu MKA, et al. (2021) Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. *Molecular cancer therapeutics*, 20(3), 564.

DiScala M, et al. (2020) Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. *PloS one*, 15(6), e0234146.

Kutys ML, et al. (2020) Uncovering mutation-specific morphogenic phenotypes and paracrine-mediated vessel dysfunction in a biomimetic vascularized mammary duct platform. *Nature communications*, 11(1), 3377.

Piasecka D, et al. (2020) Upregulation of HIF1- α via an NF- κ B/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli. *Neoplasia (New York, N.Y.)*, 22(11), 576.

Wang M, et al. (2019) A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. *Oncogene*, 38(22), 4264.

Robichaux JP, et al. (2019) Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. *Cancer*

cell, 36(4), 444.

Ahn S, et al. (2019) Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. *Cancer immunology research*, 7(5), 773.

Takegawa N, et al. (2019) [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. *International journal of cancer*, 145(12), 3414.

Wang M, et al. (2019) Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. *Cell death discovery*, 5, 153.

Shin DH, et al. (2018) Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. *Molecular cancer therapeutics*, 17(9), 2024.

Kitowska K, et al. (2018) Progesterone impairs Herceptin effect on breast cancer cells. *Oncology letters*, 15(2), 1817.